Moreover, we tested anti-PD1 therapy with regorafenib at 10 mg/kg against spontaneous HCCs developed in Mst1/Mst2-deficient mice and found that it significantly delayed tumor growth (figure 4E). Here, STK3 is linked to neoplasm.